AZYO Aziyo Biologics

Aziyo Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

Aziyo Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

SILVER SPRING, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 1, 2021. Management will host a conference call to review the Company’s financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the Aziyo Biologics, Inc. website at under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (833) 665-0667 (US/Canada) or (914) 987-7319 (International) and use the conference ID number 4158569 approximately ten minutes prior to the start time.

About Aziyo Biologics

Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit .        

Media:

Courtney Guyer

Aziyo Biologics, Inc.

Investors:

Leigh Salvo

Gilmartin Group



EN
15/02/2021

Underlying

AZYOAziyo Biologics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platfor...

New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices — The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a new study describing the bioinductive effects of its antibiotic-eluting CIED biologic envelope in the . Researchers ...

July 1, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Me...

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, has been recognized with two prestigious honors—Innovation and Product Launches—in the 2025 Medical Device Network Excellence Awards. The awards celebrate El...

June 26, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed ...

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method — Innovative approach accelerates new product development and testing — SILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a peer-reviewed article describing the first validated method for measuring antibiotic release from a biologic envelope. The novel method demonstrates in vitro elution that closely replicates preclinical studies, ...

May 28, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Announces Strong First Quarter 2025 Financial Results Driven by...

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™. In its first quarter post-launch, EluPro demonstrated strong momentum, establishing...

May 8, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Transitions to Direct Distribution of Its Cardiovascular Produc...

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc. The move allows Elutia to directly capture top-...

May 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch